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Abstract: We genetically characterized 22 Swiss patients who had been diagnosed with Stargardt
disease after clinical examination. We identified in 11 patients (50%) pathogenic bi-allelic ABCA4
variants, c.1760+2T>C and c.4496T>C being novel. The dominantly inherited pathogenic ELOVL4
c.810C>G p.(Tyr270*) and PRPH2-c.422A>G p.(Tyr141Cys) variants were identified in eight (36%) and
three patients (14%), respectively. All patients harboring the ELOVL4 c.810C>G p.(Tyr270*) variant
originated from the same small Swiss area, identifying a founder mutation. In the ABCA4 and ELOVL4
cohorts, the clinical phenotypes of “flecks”, “atrophy”, and “bull’s eye like” were observed by fundus
examination. In the small number of patients harboring the pathogenic PRPH2 variant, we could
observe both “flecks” and “atrophy” clinical phenotypes. The onset of disease, progression of visual
acuity and clinical symptoms, inheritance patterns, fundus autofluorescence, and optical coherence
tomography did not allow discrimination between the genetically heterogeneous Stargardt patients.
The genetic heterogeneity observed in the relatively small Swiss population should prompt systematic
genetic testing of clinically diagnosed Stargardt patients. The resulting molecular diagnostic is
required to prevent potentially harmful vitamin A supplementation, to provide genetic counseling
with respect to inheritance, and to schedule appropriate follow-up visits in the presence of increased
risk of choroidal neovascularization.
Keywords: macula dystrophy; retinal degeneration; choroidal dystrophy; Stargardt disease; central
areolar choroidal dystrophy; genetic analyses; recessive inheritance; dominant inheritance
1. Introduction
With a prevalence of 8–10/100,000, Stargardt disease is the most frequent inherited
macular dystrophy (MD) in both children and adults [1]. The clinical spectrum of Stargardt
disease is highly variable in terms of age of onset, phenotypical features, progression rate,
and the extension of retinal involvement [2]. The first manifestations can already occur
during the first two decades of life (juvenile-onset) [3], and the second peak of incidence
is during early adulthood [1]. A significant number of patients become affected in late
adulthood by the so-called “late-onset foveal sparing Stargardt disease” [4]. In terms
of symptoms, the most often reported ones are visual impairment [2], bilateral central
visual loss, dyschromatopsia, central scotoma [1], and more seldom photophobia or slow
dark adaptation. The classical description of Stargardt disease relates to retinal flecks
around the macula, variably extending to the mid-peripheral retina, and a progressive
macular atrophy over time [2]. However, the disease’s phenotypical spectrum is much
broader and includes: macular atrophy without flecks, bull’s-eye maculopathy-like, fundus
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flavimaculatus (flecks without atrophy), foveal-sparing phenotype, cone-rod dystrophy [5],
and retinitis pigmentosa-like [6].
The classical form of Stargardt disease is caused by homozygous or compound het-
erozygous pathogenic variants in the adenosine triphosphate (ATP)-binding cassette (ABC)
transporter 4 (ABCA4) gene. ABCA4 is exclusively expressed in photoreceptors, where
it is located on the outer segments disc membranes of rods and cones. Its function is
the translocation of retinoids produced during the visual cycle, after the photobleaching-
induced isomerization of 11-cis-retinal: N-retinylidene phosphatidylethanolamine and
all-trans-retinal [7]. Pathogenic ABCA4 variants, therefore, lead to the defective transport
of retinoids [2]. Thus, the byproducts of the visual cycle (lipofuscin being the main one) ac-
cumulate in the photoreceptors’ outer segments and then in the retinal pigment epithelium
(RPE) cells because of the disc shedding process [7]. This accumulation of lipofuscin and its
highly toxic component A2E (N-retinylidene-N-retinylethanolamine) in RPE cells leads to
their dysfunction and eventually to their death, followed by one of the photoreceptors [1],
this substance having a very high epithelial and neuronal toxicity [7].
An inverse relationship between the residual ABCA4 function and the disease severity
is consequently intuitive [4]. Nevertheless, genotype–phenotype correlations are limited
among the more than 6000 pathogenic variants reported in the literature [8]. Missense vari-
ants, non-canonical splice site variants, and deep intronic variants are usually associated
with a milder phenotype, even though they can be the origin of fast disease progression
as well [9–11]. Nonsense and frameshift variants are typically responsible for more se-
vere presentations, with an earlier vision loss and a worse prognosis, although in these
cases as well, exceptions do occur [7]. Compound heterozygosity furthermore hampers
genotype–phenotype correlations. For example, the most common pathogenic ABCA4
variant c.5882G>A p.(Gly1961Glu) is linked to a mild disease in a homozygous state, but in
a compound heterozygous state, milder to much more severe disease phenotypes are
observed [8,12]
Similar clinical phenotypes that present in patients affected by ABCA4-linked autoso-
mal recessive Stargardt disease (STGD1) can also be observed in ELOVL4-linked autosomal
dominant Stargardt disease (STGD3) [13,14], in PROM1-linked autosomal dominant Star-
gardt disease (STGD4) [15], and in an autosomal dominant macular dystrophy associated
with a c.422A>G p.(Tyr141Cys) PRPH2 variant [16].
The ubiquitously expressed ELOVL4 gene encodes the integral membrane fatty acid
elongase ELOVL4, which elongates very long chain (VLC) saturated and polyunsaturated
fatty acids (PUFA). In the retina, VLC-PUFA are enriched in the phosphatidylcholine
fraction of retinal lipids and are tightly associated with opsins [17]. Two pathogenic
frameshift variants, a 1-bp and a 5-bp deletion, and a c.810C>G, p.(Tyr270*) nonsense
variant have been identified so far [14,18]. These truncated ELOVL4 proteins mislocalize to
the Golgi or form perinuclear aggregates by physically interacting by a so-called dominant
negative effect with wild-type ELOVL4, leading to cellular stress and eventually cell
death [17,19].
The autosomal dominant Stargardt-like pattern dystrophy associated with the pathogenic
PRPH2 c.422A>G p.(Tyr141Cys) has some reported variability in clinical phenotypes, includ-
ing butterfly-shaped pattern dystrophy, adult-onset foveomacular dystrophy, fundus flavi-
maculatus, and geographic atrophy [16,20]. PRPH2 encodes the transmembrane tetraspanin
glycoprotein Peripherin 2, previously known as RDS (retinal degeneration slow). Peripherin 2
is specifically located to the rim region of cone and rod outer segment discs, where it forms
complexes with its non-glycosylated homolog ROM-1 (rod outer segment membrane 1) [21].
As peripherin-2 is required for the morphogenesis of the photoreceptors’ outer segments,
its deficiency leads to cell disorganization and eventually apoptosis [22,23].
Given the genetic heterogeneity of patients presenting a Stargardt-like phenotype,
we aimed at deciphering a genotype–phenotype correlation through the study of a cohort
of Swiss patients.
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2. Materials and Methods
2.1. Patients
We included patients who had their initial visit or follow-up visits in the Department of
Ophthalmology of the University Hospital of Bern (Inselspital, Bern, Switzerland) between
2018 and 2020. All patients provided written consent for genetic analyses and use of
anonymized data for scientific purposes. In this retrospectively constituted cohort, we then
included all the patients who had a confirmed genetic diagnosis of STGD1 (with≥2 ABCA4
pathogenic variants), STGD3 (all with the ELOVL4 c.810C>G p.(Tyr270*) variant) and
PRPH2-c.422A>G p.(Tyr141Cys)-associated autosomal dominant macular dystrophy.
2.2. Molecular Genetic Analysis
Two to five ml peripheral venous blood samples were collected in EDTA-containing
tubes (S-Monovette®, Sarstedt, Nümbrecht, Germany). DNA was extracted from the EDTA
blood using the Prepito DNA Blood 600 Kit (Qiagen, Hilden, Germany). The molecular
genetic analysis was performed by exome sequencing using Trusight One normal or
Trusight One expanded sequencing panels (Illumina) and next-generation sequencer MiSeq
or NextSeq 500 (Illumina, San Diego, CA, USA). Sequence alignment and local realignment
to the human reference genome (GRCh37hg19) were performed with Biomedical Genomics
Workbench (Qiagen Bioinformatics, Hilden, Germany). Variants with an allele frequency
<5% in the coding regions and the flanking intronic regions (± 8 bp) were evaluated.
The following databases were used for data interpretation: dbSNP137, dbSNP150, 1000
Genomes, Exome variant server, NHLBI Exome Sequencing Project (ESP, ESP6500SI-V2),
Genome Aggregation Database (gnomAD, v.2.0.2), ClinVar, HGMD professional, Intervar,
VarSome, NCBI- and ENSEMBL databases. PCR amplification (Thermo Fisher Scientific,
Waltham, MA, USA) and Sanger sequencing on an ABI Prism 3500XL Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA) confirmed pathogenic and likely pathogenic
sequence variants. In case of very high clinical suspicion of a particular mutation, or in
case of analysis of the relatives of a patient who already got a genetic diagnosis, DNA was
extracted from the mouth mucosal cell swabs (FAB-SWAB, Loci Forensic Products, Nieuw-
Vennep, The Netherlands) via Qiagen-Kit Mini and the relevant exons directly analyzed by
Sanger sequencing.
2.3. Clinical Data
We performed a medical record review on the patients. The collected data included
the patients’ sex and age, medical history (general and ophthalmological, with a special
focus on the age at the first symptoms presentation and on the described ophthalmological
symptoms), best corrected visual acuity and its evolution, and finally, family history. For ev-
ery patient, we analyzed spectral domain optic coherence tomography (SD-OCT) images
and autofluorescence pictures. These images were acquired using the Heidelberg Spec-
tralis HRA+OCT device (Heidelberg Engineering, Heidelberg, Germany) and interpreted
independently by three of the authors.
3. Results
The ABCA4 cohort is composed of 11 unrelated patients, 9 females and 2 males.
Their family trees are drawn in Figure 1 and their genotypes described in Table 1. Genetic
analyses identified compound heterozygosity in all patients, including two novel ABCA4
variants: a splice variant c.1760+2T>C p.? and a missense variant c.4496T>C p.(Leu1499Pro).
The first variant is classified as pathogenic and the latter as likely pathogenic according to
the criteria of the American College of Medical Genetics and Genomics (ACMG) [24]. In pa-
tient II.1 of family 7, we identified the frequent complex allele p.[(Leu541Pro;Ala1038Val)].
Compound-heterozygosity of patient III.1 of the consanguineous family 11, originat-
ing initially from the Caucasus region, was associated with a pseudo-dominant inher-
itance pattern. The affected mother was homozygous for the likely pathogenic c.1807T>C
p.(Tyr603His) variant, whereas her son was compound heterozygous for the paternally
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inherited c.4496T>C p.(Leu1499Pro) and the maternally inherited c.1807T>C p.(Tyr603His)
variants. We also checked for the presence of the frequent hypomorphic variant c.5603A>T
p.(Asn1868Ile) and identified it in patient I.2 of family 10.
Figure 1. Family trees of the ABCA4 cohort. In each pedigree, the arrow indicates the proband.
Family 1, patient II.2 (A), family 2, patient II.1 (B), family 3, patient II.2 (C), family 4, patient II.2
(D), family 5, patient II.2 (E), family 6, patient II.2 (F), family 7, patient II.1 (G), family 8, patient
III.2 (H), family 9, patient II.2 (I), family 10, patient I.2 (J), and family 11, patient III.1 (K). Identified
pathogenic variants are further detailed in Table 1.
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Table 1. Patients’ genotypes. The reference transcripts for variant numbering using A in ATG as number 1 are NM_000350.3
for ABCA4, NM_022726.3 for ELOVL4, and NM_000322.5 for PRPH2. Pathogenicity is according to the criteria of the
American College of Medical Genetics and Genomics (ACMG) [24]. VUS, variant of unknown significance.
Family/ patient Gene Variants Zygosity Pathogenicity First Description
1/II.2 ABCA4
c.673G>A p.(Val225Met) heterozygous likely pathogenic [25]
c.6119G>A
p.(Arg2040Gln) heterozygous pathogenic [4]
2/II.1 ABCA4
c.1760+2T>C p.? heterozygous pathogenic novel
c.3727T>G
p.(Tyr1243Asp) heterozygous likely pathogenic [25]
3/II.2 ABCA4
c.4124C>A
p.(Ala1375Glu) heterozygous likely pathogenic [26]
c.5377G>A
p.(Val1793Met) heterozygous likely pathogenic [26]
4/II.2 ABCA4
c.3322C>T
p.(Arg1108Cys) heterozygous pathogenic [27]
c.5882G>A
p.(Gly1961Glu) heterozygous pathogenic [27]
c.6320G>A
p.(Arg2107His) heterozygous VUS [28]
5/II.2 ABCA4
c.3758C>T
p.(Thr1253Met) heterozygous likely pathogenic [29]
c.5882G>A
p.(Gly1961Glu) heterozygous pathogenic [27]
6/II.2 ABCA4
c.634C>T p.(Arg212Cys) heterozygous pathogenic [30]
c.5882G>A
p.(Gly1961Glu) heterozygous pathogenic [27]
7/II.1 ABCA4
c.1622T>C
p.(Leu541Pro) heterozygous likely pathogenic [27]
c.2588G>C
p.[(Gly863Ala,Gly863del)] heterozygous likely pathogenic [31]
c.3113C>T
p.(Ala1038Val) heterozygous pathogenic [27]
8/III.2 ABCA4
c.2401G>A
p.(Ala801Thr) heterozygous likely pathogenic [32]
c.5018+2T>C p.? heterozygous pathogenic [33]
9/II.2 ABCA4
c.1804C>T
p.(Arg602Trp) heterozygous pathogenic [27]
c.5882G>A
p.(Gly1961Glu) heterozygous pathogenic [27]
10/I.2 ABCA4
c.1302delA
p.(Gln437Argfs*12) heterozygous pathogenic [34]
c.4297G>A
p.(Val1433Ile) heterozygous likely pathogenic [35]
11/III.1 ABCA4
c.1807T>C
p.(Tyr603His) heterozygous likely pathogenic [36]
c.4496T>C
p.(Leu1499Pro) heterozygous likely pathogenic novel
12/II.2 ELOVL4 c.810C>G p.(Tyr270*) heterozygous pathogenic [13]
13/II.1 ELOVL4 c.810C>G p.(Tyr270*) heterozygous pathogenic [13]
13/III.2 ELOVL4 c.810C>G p.(Tyr270*) heterozygous pathogenic [13]
13/III.1 ELOVL4 c.810C>G p.(Tyr270*) heterozygous pathogenic [13]
13/I.1 ELOVL4 c.810C>G p.(Tyr270*) heterozygous pathogenic [13]
14/II.4 ELOVL4 c.810C>G, p.(Tyr270*) heterozygous pathogenic [13]
15/II.3 ELOVL4 c.810C>G p.(Tyr270*) heterozygous pathogenic [13]
16/III.2 ELOVL4 c.810C>G p.(Tyr270*) heterozygous pathogenic [13]
17/II.1 PRPH2 c.422A>G p.(Tyr141Cys) heterozygous pathogenic [16]
18/II.2 PRPH2 c.422A>G p.(Tyr141Cys) heterozygous pathogenic [16]
19/III.2 PRPH2 c.422A>G p.(Tyr141Cys) heterozygous pathogenic [16]
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The median age of the patients at the time of the study (2020) was 44 years, ranging
from 18 to 69 years old. The median age at the beginning of the symptoms was 35.5 years
(range: 10–57 years old; unknown for a patient). The average duration of the disease,
measured by the time interval between the first symptoms and the year this study was
conducted was 8 years (range: 2–17 years).
The visual acuity was considered as good (≥0.5) at the final examination in 7 eyes
among the 10 patients for which we had a visual acuity value (35%). It was considered
as normal (≥0.8) [4] in 6 eyes (30%). The values and the evaluations of the visual acuities
related to the patients’ ages are represented in Figure 2 and illustrate the typical “juvenile-
onset” and “late-onset” Stargardt patients of this ABCA4 cohort.
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Figure 2. Evolution of the visual acuity in patients harboring pathogenic bi-allelic ABCA4 variants.
Best corrected visual acuity was assessed at indicated age (years), each dot indicating a clinical
examination. OD, right eye; OS, left eye. Patient descriptions in text and tables.
Out of these 11 patients, we were able to obtain clinical data from 9 of them. The most
common complaints were a progressive vision decrease (8/9; 88.89%), followed by hemer-
alopia and photophobia (4/9; 44.44%). More seldom, patients would spontaneously relate
about reading difficulties (3/9; 33.33%), color vision deterioration (1/9; 11.11%), or about
the presence of a central scotoma (1/9; 11.11%). The fundus autofluorescence and OCT
data are respectively shown in Figures 3 and 4, and the findings are summarized in Table 2.
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Figure 3. Fundus autofluorescence (FAF) imaging of patients harboring pathogenic bi-allelic ABCA4 variants. Patient 1/II.2
(A), patient 2/II.1 (B), patient 3/II.2 (C), patient 4/II.2 (D), patient 5/II.2 (E), patient 6/II.2 (F), patient 7/II.1 (G), patient
8/III.2 (H), patient 10/I.2 (J), and patient 11/III.1 (K). For each patient, the left panel shows the right eye, and the right
panel the left one. The FAF findings are described in detail in Table 2.
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Figure 4. Optical coherence tomography (OCT) of patients harboring pathogenic bi-allelic ABCA4 variants. Patient 1/II.2
(A), patient 2/II.1 (B), patient 3/II.2 (C), patient 4/II.2 (D), patient 5/II.2 (E), patient 6/II.2 (F), patient 7/II.1 (G), patient
9/II.2 (H), patient 10/I.2 (I), and patient 11/III.1 (J). For each patient, green lines on FAF images indicate the scanning
sections (left and right panels) of the OCT (middle panels). The left panels show the right eye, and the right panels the left
one. The OCT findings are described in detail in Table 2.
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Table 2. Summary of fundus autofluorescence (FAF) and optical coherence tomography (OCT) findings. EZ, ellipsoid zone; FAF, fundus autofluorescence; HOAF, hypoautofluorescence;
HPAF, hyperautofluorescence; NA, not available; OD: right eye; ONL, outer nuclear layer; OS, left eye.
Patient Gene Age Sex FAF OCT
1, II.2 ABCA4 53 F Foveal HPAF Subretinal hyperreflective deposits
2, II.1 ABCA4 18 F Central HOAF; concentric ring of HPAF Central EZ disruption with gap; ONL atrophy
3, II.2 ABCA4 18 F Foveal HOAF; central mottled pattern of HPAF and HOAF flecks Central EZ loss; central ONL atrophy
4, II.2 ABCA4 27 F Foveal HPAF; parafoveal HOAF; paramacular HPAF Central EZ loss; central ONL atrophy
5, II.2 ABCA4 69 F Mid-peripheral mottled HOAF Mid-peripheral ONL atrophy, lamellar macular hole (OD)
6, II.2 ABCA4 53 F Foveal HOAF; central mottled pattern of HPAF and HOAF flecks Central EZ disruption with gap (OS) and loss (OD); central ONL atrophy
7, II.1 ABCA4 19 F Central HOAF; HPAF flecks Central EZ loss; central ONL atrophy
8, III.2 ABCA4 30 M Central HOAF; HPAF flecks NA
9, II.2 ABCA4 44 F Central mottled pattern of HPAF and HOAF flecks Central EZ loss; central ONL atrophy
10, I.2 ABCA4 51 F Foveal HOAF; central mottled pattern of HPAF and HOAF flecks Perifoveal EZ loss; perifoveal ONL atrophy; loss of the foveal depression
11, III.1 ABCA4 53 M Extended central and peripheral HOAF; panretinal diffuse mottledpattern of HPAF and HOAF flecks
ONL atrophy; peripheral choroidal atrophy; RPE atrophy; subretinal
hyperreflective deposits
12, II.2 ELOVL4 37 F Central HOAF; concentric ring of HPAF Central EZ loss; central ONL atrophy and RPE atrophy
13, II.1 ELOVL4 46 F Multifocal areolar parafoveal HOAF; mottled pattern of HPAF andHOAF flecks; perimacular to mid-peripheral HPAF flecks
Perimacular EZ loss; perimacular ONL atrophy; subretinal
hyperreflective deposits
13, III.2 ELOVL4 19 F No special features Subfoveal hyperreflective deposits (OD)
13, III.1 ELOVL4 21 M NA No special features
13, I.1 ELOVL4 82 M Areolar HOAF; paracentral mottled pattern of HPAF and HOAF flecks ONL thinning; perimacular localised EZ loss (OS)
14, II.4 ELOVL4 48 M Central mottled pattern of HPAF and HOAF flecks Central EZ loss; central ONL atrophy; perimacular subretinalhyperreflective deposits
15, II.3 ELOVL4 34 M Subfoveal HOAF; concentric ring of HPAF Central EZ disruption with gap; central ONL atrophy
16, III.2 ELOVL4 28 F NA NA
17, II.1 PRPH2 51 F Butterfly pattern of HPAF and HOAF flecks; paramacular tomid-peripheral HPAF flecks Irregular EZ thickening
18, II.2 PRPH2 69 M Subfoveal HOAF (OS); butterfly pattern of HPAF and HOAF flecks;paramacular to mid-peripheral HPAF flecks
Central EZ loss (OS); central ONL atrophy (OS); localised ONL thinning
(OD)
19, III.2 PRPH2 39 F Central areolar HOAF; disseminated nummular HPAF Extended retinal atrophy
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Eight patients (4 females and 4 males) were part of the ELOVL4 cohort. Most of them
were related, as shown in their family trees in Figure 5. All of them originated from the
same alpine region located in the South of the Canton of Valais. They all shared the same
heterozygous pathogenic c.810C>G p.(Tyr270*) variant in the ELOVL4 gene, indicating a
founder mutation (see Table 1).
When this study was conducted in 2020, the median age of these patients was 35.5
years old (range: 19–82 years old). Their median age when they first became symptomatic
was 27 years old, with a very broad range going from around 10 to 79 years old. One patient
was still asymptomatic at his last ophthalmological control at age 23 (family 13, patient
III.1). The median duration of the disease for the 7 symptomatic patients (determined with
the same method as the one described above) was 4 years (range: 1–17 years).
Ten eyes from these 8 patients (62.5%) had a good visual acuity (≥0.5) at their last
ophthalmological check-up, whereas 7 out of them (43.8%) could even be considered as
having a normal vision (visual acuity ≥ 0.8). The evolution of their visual acuity is shown
in Figure 6. While analyzing the reported symptoms of the 7 symptomatic ELOVL4 patients,
we noticed that all of them (100%) were complaining about a progressive vision decrease.
The other reported symptoms were less common but similar to the ones of the ABCA4
cohort: reading difficulties (1/7, 14.29%), hemeralopia (1/7, 14.29%), photophobia (2/7,
28.57%), color vision deterioration (1/7, 14.29%), and central scotoma (1/7, 14.29%). The
fundus autofluorescence and OCT data are respectively shown in Figures 7 and 8, and the
findings are summarized in Table 2.
Our cohort with patients harboring the pathogenic c.422A>G, p.(Tyr141Cys) PRPH2
variant was the smallest one and counted only 3 unrelated patients, 2 females and 1 male.
Their family trees are shown in Figure 9. They all originated from a region located between
the cantons of Fribourg and Bern, indicating a possible founder effect.
In 2020, their ages were in chronological order 39, 51, and 69 years old and their
symptoms first started when they respectively were 7, 10, and 36 years old, which gave a
disease duration of 32, 41, and 33 years, which is much longer than what we had in the
two previous cohorts.
Five eyes from these three patients (83.33%) had at their last ophthalmological control
a visual acuity considered as good (≥0.5) included three (50%) who had one considered as
normal (≥0.8). Their vision evolution is schematized in Figure 10. All of them (100%) were
complaining about a progressive diminution of their vision. Only one patient (33.33%)
reported reading difficulties, one (33.33%) hemeralopia, and one (33.33%) a central scotoma.
However, none of them related about photophobia or color vision disturbances. The fundus
autofluorescence and OCT data are respectively shown in Figures 11 and 12, and the
findings are summarized in Table 2.
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Figure 5. Family trees of the ELOVL4 cohort. Family 12, patient II.2 (A), family 13, patients I.1, II.1, III.1 and III.2 (B), family
14, patient II.4 (C), family 15, patient II.3 (D), and family 16, patient III.2 (E).
Figure 6. Evolution of the visual acuity in patients harboring the pathogenic c.810C>G, p.(Tyr270*) ELOVL4 variant. Best
corrected visual acuity was assessed at indicated age (years), each dot indicating a clinical examination. OD, right eye; OS,
left eye. Patient descriptions in text and tables.
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Figure 7. Fundus autofluorescence imaging of patients harboring the pathogenic c.810C>G p.(Tyr270*) ELOVL4 variant.
Patient 12/II.2 (A), patient 13/II.1 (B), patient 13/III.2 (C), patient 13/I.1 (D), patient 14/II.4 (E), and patient 15/II.3 (F).
For each patient, the left panel shows the right eye, and the right panel the left one. The FAF findings are described in detail
in Table 2.
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Figure 8. Optical coherence tomography (OCT) of patients harboring the pathogenic c.810C>G, p.(Tyr270*) ELOVL4 variant.
Patient 12/II.2 (A), patient 13/II.1 (B), patient 13/III.2 (C), patient 13/III.1 (D), patient 13/I.1 (E), patient 14/II.4 (F), and
patient 15/II.3 (G). For each patient, green lines on FAF images indicate the scanning sections (left and right panels) of the
OCT (middle panels). The left panels show the right eye, and the right panels the left one. The OCT findings are described
in detail in Table 2.
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Figure 9. Family trees of the PRPH2 cohort. Family 17, patient II.1 (A), family 18, patient II.2 (B), and family 19, pa-
tient III.2 (C).
Figure 10. Evolution of the visual acuity in patients harboring the pathogenic c.422A>G p.(Tyr141Cys) PRPH2 variant. Best
corrected visual acuity was assessed at indicated age (years), each dot indicating a clinical examination. OD, right eye; OS,
left eye. Patient descriptions in text and tables.
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Figure 11. Fundus autofluorescence imaging of patients harboring the pathogenic c.422A>G p.(Tyr141Cys) PRPH2 variant.
Patient 17/II.1 (A), patient 18/II.2 (B), patient 19/III.2 (C). For each patient, the left panel shows the right eye, and the right
panel the left one. The FAF findings are described in detail in Table 2.
Figure 12. Optical coherence tomography (OCT) of patients harboring the pathogenic c.422A>G p.(Tyr141Cys) PRPH2
variant. Patient 17/II.1 (A), patient 18/II.2 (B), patient 19/III.2 (C). For each patient, green lines on FAF images indicate the
scanning sections (left and right panels) of the OCT (middle panels). The left panels show the right eye, and the right panels
the left one. The OCT findings are described in detail in Table 2.
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While analyzing the fundus autofluorescence images of all patients, irrespective of
their genotype, we identified three main phenotypes that we respectively named “flecks”,
“atrophy”, and “bull’s eye like”.
The “flecks” phenotype is the most prevalent one among our three cohorts: 7/11 = 63.64%
in the ABCA4 cohort, 3/6 = 50% in the ELOVL4 cohort and 2/3 = 66.67% in the PRPH2
cohort. In the “flecks” phenotype, a central mottled pattern of hyperautofluorescent and
hypoautofluorescent flecks variably extend to the mid-periphery, and we observed an almost
identical phenotype in ABCA4, ELOVL4, and PRPH2 patients (Figure 13). We observed small
differences among the patients exhibiting a “flecks” phenotype. For example, in patient
5/II.2, this phenotype was only present in the periphery and absent in the macula, which
makes it atypical for a macular dystrophy. Some other patients presented a higher number of
hyperautofluorescent flecks and a smaller mottled pattern (7/II.1 and 8/III.2) and some other
ones a pattern looking more like a butterfly-like pattern than a mottled one (17/II.1 and 18/II.2).
The next phenotype we recognized was the “atrophy” one, characterized by a variable
extent of macular atrophy. Again, we observed similar phenotypes in ABCA4, ELOVL4, and
PRPH2 patients (Figure 14). Some other patients presented a form of nummular atrophy
combined with the “flecks” phenotype (patient 13/I.1 and 13/II.2).
The last phenotype that we recognized in our case series was the “bull’s eye like”
one (Figure 15). We identified this phenotype only in patients of the ABCA4 and ELOVL4
cohort, but not the PRPH2 one. The “bull’s eye like” phenotype appears to be an early stage
of macular degeneration, as it corresponds in the OCT to the disruption of the EZ with a
gap, which is the step preceding the collapse and complete loss of the EZ. Of note, we did
not identify in our Swiss cohorts new patients affected by PROM1-p.(Arg373Cys)-linked
“bull’s eye like” macular dystrophy (STGD4) [37].
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Figure 13. “Flecks” clinical phenotype. FAF (A) and OCT (B) imaging of STGD1 patient 3/II.2 compound heterozygous for
the c.4124C>A p.(Ala1375Glu) and c.5377G>A p.(Val1793Met) ABCA4 variants. FAF (C) and OCT (D) imaging of STGD3
patient 14/II.4 harboring the pathogenic c.810C>G p.(Tyr270*) ELOVL4 variant. FAF (E) and OCT (F) imaging of patient
17/II.1 affected by c.422A>G p.(Tyr141Cys) PRPH2-associated autosomal dominant Stargardt-like macular dystrophy.
Figure 14. “Atrophy” clinical phenotype. FAF (A) and OCT (B) imaging of STGD1 patient 11/III.1 compound heterozygous
for the c.1807T>C p.(Tyr603His) and c.4496T>C p.(Leu1499Pro) ABCA4 variants. FAF (C) and OCT (D) imaging of STGD3
patient 12/II.2 harboring the pathogenic c.810C>G p.(Tyr270*) ELOVL4 variant. FAF (E) and OCT (F) imaging of patient
19/III.2 affected by c.422A>G p.(Tyr141Cys) PRPH2-associated autosomal dominant Stargardt-like macular dystrophy.
Figure 15. “Bull’s eye like” clinical phenotype. FAF (A) and OCT (B) imaging of STGD1 patient 2/II.1 compound
heterozygous for the c.1760+2T>C p.? and c.3727T>G p.(Tyr1243Asp) ABCA4 variants. FAF (C) and OCT (D) imaging of
STGD3 patient 12/II.2 harboring the pathogenic c.810C>G p.(Tyr270*) ELOVL4 variant.
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4. Discussion
The purpose of our study was to determine whether clinical symptoms, onset of
disease, family history, fundus autofluorescence and/or OCT findings were sufficient to
discriminate among our patients between autosomal recessive ABCA4-associated STGD1,
autosomal dominant c.810C>G p.(Tyr270*) ELOVL4-associated STGD3 and the autosomal
dominant c.422A>G p.(Tyr141Cys) PRPH2-associated Stargardt-like macular dystrophy.
Clinical diagnosis is difficult because these disorders linked to different genes lead to
the same clinical phenotypes. Incomplete penetrance can furthermore mask a dominant
inheritance in some isolated cases.
The main clinical symptom of progressive vision diminution was reported in 89% of
ABCA4 patients and in 100% of symptomatic ELOVL4 and PRPH2 patients. Patients of the
ABCA4 and ELOVL4 cohorts also exhibited other classical symptoms reported in Stargardt
disease: dyschromatopsia, central scotoma, photophobia, and delayed dark adaptation [1,2].
Reading difficulties are a direct consequence of these symptoms and are sometimes missed
if not especially asked about. Patients of the PRPH2 cohort did not report photophobia and
dyschromatopsia, but this is very likely due to the small size of this cohort. Indeed, only a
minority of patients of the ABCA4 and ELOVL4 cohorts reported photophobia, respectively
44% and 29%, and dyschromatopsia, respectively 11.11% and 14.29%.
The onset and progression of macular dystrophies can be objectively evaluated by
assessing visual acuity (VA), despite some variability due to tiredness, ocular dryness,
or presence of cataract [38,39]. We observed the typical “juvenile-onset” and “late-onset”
patients in the ABCA4 cohort (onset 10-57 years old; median 35.5 years old) [1,4,14]. In
the ELOVL4 cohort too (onset 10-79 years old; median 27 years old), we observed a rapid
vision worsening among the youngest patients (12/II.2, 13/III.2 and 15/II.3) and a more
conserved VA among the oldest ones (13/I.1, 13/II.1 and 14/II.4). The onset of clinical
symptoms in PRPH2-associated autosomal dominant Stargardt-like macular dystrophy was
reported to start later in life (≥50 years old) [40], which could have allowed to distinguish
them from the ABCA4 and ELOVL4 patients. Nevertheless, the onset of clinical symptoms
occurred in our small PRPH2 cohort during childhood in two out of three patients and
at age 36 for the third patient. Of note, OCT imaging was not useful for the differential
diagnosis, as almost all patients showed variable extents of outer nuclear layer (ONL)
atrophy and ellipsoid zone (EZ) disruption (with a gap) or EZ loss.
In the ABCA4 cohort, five patients were affected by “juvenile-onset” STGD1 and
6 patients by “late-onset” STGD1. Pathogenic variants associated with “juvenile-onset”
included the complex p.[(Leu541Pro;Ala1038Val)] (family 7, patient II.1) and the canonical
splice variants c.1760+2T>C (family 2, patient II.1) and c.5018+2T>C (family 8, patient
III.2). The hypomorphic variant c.5882G>A p.(Gly1961Glu) was also associated with
“juvenile-onset” STGD1 in patient II.2 of family 4, with the additional variants c.3322C>T
p.(Arg1108Cys) and c.6320G>A p.(Arg2107His). The hypomorphic variant c.5882G>A
p.(Gly1961Glu) was present in three additional patients affected by “late-onset” STGD1.
The second pathogenic ABCA4 variant in these compound heterozygous patients was
respectively c.634C>T p.(Arg212Cys) (family 6, patient II.2), c.1804C>T p.(Arg602Trp)
(family 9, patient II.2) and c.3758C>T p.(Thr1253Met) (family 5, patient II.2). This last
patient had been initially diagnosed with a “slow progressing retinitis pigmentosa” and still
had a visual acuity of 1.0 at the age of 70. Genetic analysis did not identify any pathogenic
variant in any other gene associated with retinal dystrophy, except ABCA4. Whether this
atypical clinical phenotype is due to the presence of the second pathogenic c.3758C>T
p.(Thr1253Met) variant remains elusive, because, to our best knowledge, no other identical
compound heterozygous patient has been identified so far. Visual acuity of 0.8-1.0 was
also relatively preserved in patient I.2 of family 10. The milder clinical phenotype may be
linked to the presence of the c.4397G>A p.(Val1433Ile) variant, but the clinical symptoms
could be aggravated by the frequent hypomorphic c.5603C>T p.(Asn1868Ile) variant also
present in this patient.
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Family history should theoretically allow for discrimination between the autosomal
recessive STGD1 and the dominantly inherited macular dystrophies. However, the ABCA4
cohort includes family 11 with a pseudo-dominant inheritance pattern. Furthermore, pa-
tient 14/II.4, although heterozygous for the autosomal dominant ELOVL4 variant, is the
only one affected in his family and exhibits a family tree that would be compatible with an
autosomal recessive inheritance pattern. This is consistent with the reported incomplete
penetrance and variable expressivity in the presence of pathogenic ELOVL4 variants [19,41].
Similarly, patient 18/II.2 is a heterozygous carrier of the autosomal dominant PRPH2
variant, but the only one symptomatic in his family. Again, PRPH2-associated autosomal
dominant macular dystrophies are known to have highly heterogeneous phenotypes, vari-
able expressivity, and incomplete penetrance [40,42]. Moreover, the PRPH2 p.(Tyr141Cys)
variant can cause choroidal neovascularization in older patients [20]. This clinical pheno-
type at this age can easily be confused with an exudative age-related macular degeneration
(AMD). This was actually the case for the mother of patient II.1 in family 17. Because of
these many confounders, incomplete penetrance, variable expressivity, unknown family,
adoption, consanguinity, early deaths, missed or false diagnosis, the inheritance pattern
alone is not sufficient to distinguish between ABCA4-, ELOVL4- and PRPH2-linked macu-
lar dystrophies.
We did not perform quantitative fundus autofluorescence (qAF) in our cohorts [43].
qAF was shown to be higher in patients harboring pathogenic ABCA4 variants, thus giving
an interesting diagnostic tool for STGD1 [44]. However, high qAF levels were also observed
in PRPH2-associated autosomal dominant Stargardt-like macular dystrophy, limiting its
clinical relevance in the differential diagnosis of Stargardt and Stargardt-like macular
dystrophies [45].
5. Conclusions
Clinical diagnosis is not sufficient to discriminate between patients affected by au-
tosomal recessive ABCA4-associated STGD1, autosomal dominant c.810C>G p.(Tyr270*)
ELOVL4-associated STGD3 and the autosomal dominant c.422A>G p.(Tyr141Cys) PRPH2-
associated Stargardt-like macular dystrophy. Even a small population sample of fewer
than 8 million people like the Swiss population harbors all the diversity of Stargardt and
Stargardt-like phenotypes. Therefore, genetic testing is required for all these patients.
The c.810C>G p.(Tyr270*) variant in the ELOVL4 should be suspected and specifically
tested for in all patients originating from that small mountain region in the Southern part
of the Canton of Valais. A clear molecular diagnosis in Stargardt and Stargardt-like patients
also has some direct benefits for patients. First, genetically confirmed STGD1 patients
should stop any vitamin A supplementation to avoid an increase in lipofuscin deposition
in the RPE [46]. Second, follow-up controls in patients affected by c.422A>G p.(Tyr141Cys)
PRPH2-associated Stargardt-like macular dystrophy will carefully evaluate the risk to
develop choroidal neovascularization, which could lead to hemorrhages and subsequent
loss of their residual visual acuity [20]. When appropriate, these patients could then benefit
from anti-VEGF intravitreal injections. Third, the molecular diagnosis is necessary to
establish autosomal recessive or autosomal dominant inheritance, a prerequisite for family
planning and risk calculations. Finally, even though no treatment currently exist for these
three macular dystrophies, when therapy will be available, only patients with a confirmed
molecular diagnosis will benefit from it.
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